Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes
Open Access
- 19 November 2003
- journal article
- website
- Published by Wiley in British Journal of Haematology
- Vol. 123 (5) , 879-885
- https://doi.org/10.1046/j.1365-2141.2003.04713.x
Abstract
Summary. The deletion (5q) karyotype [del (5q)] in patients with myelodysplastic syndrome (MDS) is considered a good risk feature, while the impact of del (5q) combined with other karyotypic abnormalities [del (5q)+] is less well defined. We analysed the outcome of haematopoietic cell transplants (HCT) in patients with MDS with del (5q) or del (5q)+. Fifty‐seven patients, aged 6–72 years, with MDS and del (5q) abnormalities received HCT from related (n = 32) or unrelated (n = 25) donors. By French–American–British (FAB) criteria, 27 patients had refractory anaemia (RA), 10 RA with excess blasts (RAEB), eight RAEB in transformation (RAEB‐T) and 12 acute myeloid leukaemia evolving from MDS (tAML). Non‐relapse mortality at 1‐year post‐transplantation was 30% for del (5q) and 38% for del (5q)+ patients. Relapse occurred in one of 20 del (5q) patients and 15 of 37 del (5q)+ patients (P = 0·001). After adjusting for del (5q) status, blast count (+. The indication for transplantation in patients with del (5q) was generally severe cytopenias, compared with disease progression to a more advanced FAB stage in patients with del (5q)+. Conceivably, outcome for patients with del (5q)+ would be improved with transplantation earlier in the disease course.Keywords
This publication has 14 references indexed in Scilit:
- Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cellsBlood, 2003
- Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantationBlood, 2003
- A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q− syndrome from refractory anemia in primary myelodysplastic syndromeLeukemia Research, 2003
- Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeBlood, 2002
- Myeloid Disorders with Deletion of 5q as the Sole Karyotypic Abnormality: The Clinical and Pathologic SpectrumLeukemia & Lymphoma, 2002
- Major-Histocompatibility-Complex Class I Alleles and Antigens in Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2001
- Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiationTransplantation and Cellular Therapy, 2001
- Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor PrognosisJournal of Clinical Oncology, 2001
- Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantationBone Marrow Transplantation, 1998
- Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.Journal of Clinical Oncology, 1996